Page 86 - Biomarkers for risk stratification and guidance in heart failure

Which heart failure patients profit from natriuretic peptide-guided therapy?
Berger et al. (n = 188)8
UPSTEP (n = 268)11
TIME-CHF (n = 622)14,17
Signal-HF (n = 252)13
PROTECT (n = 151)10
PRIMA (n = 345)9
Troughton et al. (n = 69)15
BATTLESCARRED (n = 242)12
Overall (n = 2137)
4
85
Table 1 Baseline characteristics from participating studies
Age (years)
Age ≥75 years
Male gender
BMI (kg/m2 ) (n = 1591)
73.5 ± 10.6 1123 (53%) 1406 (66%) 26.5 ± 4.8
74.0 ± 9.2 138 (57%) 157 (65%) 26.8 ± 4.9
70.0 ± 9.9
72.2 ± 11.9
63.3 ± 14.0 38 (25%)
127 (n = 84%) na
77.8 ± 7.6 183 (73%) 180 (71%) na
76.9 ± 7.6 380 (61%) 369 (59%) 25.6 ± 4.4
70.8 ± 9.8 105 (39%) 196 (73%) 27.3 ± 4.8
71.1 ± 11.8 88 (47%) 125 (66%) 27.1 ± 5.2
Hypertension (n = 2129)
1251 (59%)
117 (48%)
45 (66% of 68)
167
(49% of 338)
79 (52%)
139 (55%)
462 (74%)
116 (43%)
126 (67%)
Renal failure (n = 1985) CVI/TIA (n = 1986 Diabetes
COPD
524 (26%) 325 (16%) 668 (31%) 364 (17%) 249 (14%) 186 (12%) 1163 (54%) 1731 (85%) 301 (15%) 105 (5%) 32 \[25 - 40\]
63 (26%) 52 (21%) 52 (21%) 52 (21%) 30 (12%) na
16 (23%) 19 (28%) 16 (23%) 23 (33%) 12 (17%) 5 (7%)
14 (20%) 69 (100%) 0
47 (14% of 344) 66 (19%)
91 (26%)
59 (17%)
na
na
63 (42%) 31 (21%) na
na
83 (55%) 151 (100%) 0
0
26 \[20 - 34\]
6 (2%)
355 (57%) 98 (16%) 222 (36%) 124 (20%) 124 (20%) 86 (14%) 473 (76%) 499 (80%) 123 (20%) 0
7 (3%)
39 (15%) 85 (32%) 17 (6%)
18 (15%) 24 (9%) 184 (69%) 268 (100%) 0
0
na
30 (16%) 21 (11%) 86 (46%) 30 (16%) na
PVD (n = 1798) Cancer (n = 1554) NYHA ≥ III
LVEF ≤45%*
65 (19%)
0 (0%)
LVEF >45%*
LVEF unknown LVEF (%) (n = 1672)
78 (37%)
84 (27%)
5 (2%)
11 (6%)
Creatinine (μmol/L) (n = 2125)
109
\[88.2 - 140\]
110 \[90 - 130\]
90 \[80 - 110\]
121
\[101 - 158\]
124 \[97 - 150\]
95 \[76 - 117\] (n = 242)
100 \[83 - 126\] (n = 264)
115 \[89 - 149\]
NT-proBNP or BNP (pg/mL)
2645
\[1434 - 5088\] (excl UPSTEP)
2001
\[1236 - 2974\]
1467
\[1077 - 2807\]
2950
\[1319 - 5445\]
2118
\[1122 - 3831\]
2363
\[1373 - 4040\]
3836
\[1916 - 6905\]
609
\[356 - 947\]†
2280
\[1256 - 5193\]
56 (23%)
74 (21%)
96 (38%)
183 (93%)
134 (63%)
229 (73%)
204 (98%)
177 (94%)
30 (12%)
0
27 \[21 - 34)
32 (9%)
43 (17%)
0
40 \[28 - 53\] (n = 212)
34 \[25 - 48\] (n = 313)
34 (25 - 38\] (n = 209)
32 \[25 - 42\] 108 \[87 - 140\]
30 \[22 - 35\] (n = 96)
24 (35%)
167 (48%)
53 (77%)
199 (58%)
27.4 ± 4.8 (n = 67)
26.5 ± 5.0 (n = 238)
47 (14% of 343)
24 (10%)
na
30 (12%)
53 (21%)
28 (11%)